Is it possible to decrease the rate of Saphylococcus aureus peritonitis?

Peritoneal Dialysis International

Volumn 16, Issue 5, 1996, Pages 446-447

  Piraino, Beth ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PSEUDOMONIC ACID; RIFAMPICIN;

BACTERIAL PERITONITIS; EDITORIAL; HUMAN; INFECTION RATE; INFECTIOUS COMPLICATION; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0029908424     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601600506     Document Type: Editorial

References (10)

1. Kim D, Tapson J, Wu G, Khanna R, Vas SI, Oreopoulos DG. Staph aureus peritonitis in patients on continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs 1984; 30:494-7.
2. Wanten GJA, van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by Staphy lococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study. Perit Dial Int 1996; 16:352-6.
3. Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322:505-9.
4. Lye WC, Leong SO, van der Straaten J, Lee EJC. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications Inc., 1994; 10:163-5.
5. Zimmennan SW, Ahrens E, Johnson CA, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18:225-31.
6. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. Perit Dial Int 1994; 14:137-44.
7. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. Arandomized trial of Staphy lococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695-700.
8. Perez-Fontan M, Garcia-Falcon T, Resales M, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22:708-12.
9. Coles, GA. The Mupirocin Study Group. The effect of intranasal mupirocin on CAPD exit site infection. J Am Soc Nephrol 1994; 5:439.
10. Gupta B, Bernardini J, Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis (in press).